Cordis Corp., the stent-making division of Johnson & Johnson (NYSE:JNJ), landed a new U.S. regulatory win for its next-generation Adroit 6F Guiding Catheter, which the company said can handle more sophisticated cases than earlier versions.
The company is calling the Adroit 6F an "innovative hybrid braid wire" device that makes it easier for doctors to treat complex lesions and use the radial approach to catheterization.
"Our vision at Cordis is to transform cardiovascular care, a field in which incredible progress has been made over the last decade, but one in which much more remains to be done," global president Celine Martin said in a statement.
The J&J subsidiary recently acquired Flexible Stenting Solutions as part of turning its back on the coronary stents market in favor of the endovascular arena.
